GRAIL Partners with Epic to Enhance Access to Multi-Cancer Early Detection Test Nationwide
GRAIL, Inc., a pioneering healthcare company focused on the early detection of cancer, has recently announced a significant partnership with Epic, a leading electronic health record (EHR) platform. This collaboration aims to integrate GRAIL's Galleri® multi-cancer early detection test into Epic's system, enabling healthcare providers across health systems in the United States to seamlessly access and order the test within their existing workflows.
The Galleri test is a groundbreaking tool that allows for the detection of over 50 types of cancer before symptoms arise, thereby significantly improving the chances of successful treatment. Despite the availability of screening for five specific cancers in the U.S., over 70% of cancer-related deaths are caused by cancers that currently lack established screening protocols. With the integration of this test into the Epic platform, GRAIL aims to enhance early detection practices and support health systems in adopting this innovative technology.
The collaboration between GRAIL and Epic is centered around the integration of the Galleri test using Epic Aura, which is designed to streamline the ordering process directly at the point of care. This integration will allow healthcare providers to easily manage patient follow-ups by receiving test results and handling them within their existing EHR environment. This functionality is anticipated to significantly reduce administrative burdens and minimize manual processes for clinicians, ultimately improving the overall patient experience.
Josh Ofman, President at GRAIL, emphasized the importance of this collaboration, stating, "We are reducing operational barriers and making it easier for healthcare providers to incorporate the Galleri test into routine care, with the ultimate goal of supporting early cancer detection when outcomes may be better."
As part of the initial stages of this partnership, implementation planning began in early 2026, with an emphasis on early adopter programs and necessary integrations. GRAIL will work in tandem with Epic and AWS, its preferred cloud provider, alongside various health systems and community healthcare providers to ensure successful deployment, training, and alignment of workflows. According to current projections, broad availability of the Galleri test through the Epic platform is expected by the end of 2026.
Alan Hutchison, Vice President at Epic, highlighted how the integration will foster collaboration among healthcare organizations by removing administrative barriers, thus advancing early cancer detection efforts and contributing to better survival rates.
Dr. Philip Oravetz, Chief Population Health Officer at Ochsner Health, noted the advantages of embedding the Galleri test directly into their EHR infrastructure. This careful integration is intended to reduce administrative workload, support effective patient identification, and streamline the testing process within established clinical workflows.
This integration is not just a technological advancement; it's a step toward transforming the approach to cancer detection in healthcare systems across the nation. By empowering healthcare professionals with tools that simplify the screening process, GRAIL hopes to contribute significantly to public health, lowering cancer mortality rates in the long term. Health systems eager to incorporate the Galleri test are encouraged to find out more at galleri.com/health-systems.
Founded with the vision to transform cancer care through early detection, GRAIL leverages state-of-the-art technology, including next-generation sequencing and machine learning, to detect cancer at its earliest and most treatable stages. The company's mission aligns with its commitment to alleviate the global burden of cancer through innovative diagnostic solutions.
The Galleri test stands out for its ability to significantly increase cancer detection rates, especially when used in conjunction with standard screening recommendations. As the healthcare landscape continues to evolve, partnerships like the one between GRAIL and Epic underscore the potential of technology to improve patient outcomes and shape the future of cancer care.
Significance of the Galleri Test
The Galleri test is a groundbreaking tool that allows for the detection of over 50 types of cancer before symptoms arise, thereby significantly improving the chances of successful treatment. Despite the availability of screening for five specific cancers in the U.S., over 70% of cancer-related deaths are caused by cancers that currently lack established screening protocols. With the integration of this test into the Epic platform, GRAIL aims to enhance early detection practices and support health systems in adopting this innovative technology.
Collaboration Objectives
The collaboration between GRAIL and Epic is centered around the integration of the Galleri test using Epic Aura, which is designed to streamline the ordering process directly at the point of care. This integration will allow healthcare providers to easily manage patient follow-ups by receiving test results and handling them within their existing EHR environment. This functionality is anticipated to significantly reduce administrative burdens and minimize manual processes for clinicians, ultimately improving the overall patient experience.
Josh Ofman, President at GRAIL, emphasized the importance of this collaboration, stating, "We are reducing operational barriers and making it easier for healthcare providers to incorporate the Galleri test into routine care, with the ultimate goal of supporting early cancer detection when outcomes may be better."
Implementation Timeline and Collaborations
As part of the initial stages of this partnership, implementation planning began in early 2026, with an emphasis on early adopter programs and necessary integrations. GRAIL will work in tandem with Epic and AWS, its preferred cloud provider, alongside various health systems and community healthcare providers to ensure successful deployment, training, and alignment of workflows. According to current projections, broad availability of the Galleri test through the Epic platform is expected by the end of 2026.
Alan Hutchison, Vice President at Epic, highlighted how the integration will foster collaboration among healthcare organizations by removing administrative barriers, thus advancing early cancer detection efforts and contributing to better survival rates.
Dr. Philip Oravetz, Chief Population Health Officer at Ochsner Health, noted the advantages of embedding the Galleri test directly into their EHR infrastructure. This careful integration is intended to reduce administrative workload, support effective patient identification, and streamline the testing process within established clinical workflows.
Looking Ahead
This integration is not just a technological advancement; it's a step toward transforming the approach to cancer detection in healthcare systems across the nation. By empowering healthcare professionals with tools that simplify the screening process, GRAIL hopes to contribute significantly to public health, lowering cancer mortality rates in the long term. Health systems eager to incorporate the Galleri test are encouraged to find out more at galleri.com/health-systems.
About GRAIL
Founded with the vision to transform cancer care through early detection, GRAIL leverages state-of-the-art technology, including next-generation sequencing and machine learning, to detect cancer at its earliest and most treatable stages. The company's mission aligns with its commitment to alleviate the global burden of cancer through innovative diagnostic solutions.
The Galleri test stands out for its ability to significantly increase cancer detection rates, especially when used in conjunction with standard screening recommendations. As the healthcare landscape continues to evolve, partnerships like the one between GRAIL and Epic underscore the potential of technology to improve patient outcomes and shape the future of cancer care.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.